Thalidomide-O-COOH

 CAS No.: 1061605-21-7  Cat No.: BP-100010  Purity: ≥ 98% 4.5  

Thalidomide-O-COOH is a specialized E3 Ligase Ligand-Linker Conjugate designed for use in PROTAC (Proteolysis Targeting Chimeras) drug development. As a derivative of thalidomide functionalized with a carboxylic acid handle, Thalidomide-O-COOH enables efficient conjugation to target-binding ligands, facilitating the construction of bifunctional molecules that recruit the cereblon (CRBN) E3 ubiquitin ligase. Through the PROTAC mechanism, these chimeric compounds promote the ubiquitination and subsequent proteasomal degradation of target proteins, offering a powerful approach for targeted protein knockdown in research and therapeutic applications. Thalidomide-O-COOH is ideal for medicinal chemists and drug discovery teams looking to develop next-generation targeted protein degraders, and can be applied in diverse areas such as oncology, immunology, and neuroscience.

Thalidomide-O-COOH

Structure of 1061605-21-7

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
E3 Ligase Ligand-Linker Conjugate
Molecular Formula
C15H12N2O7
Molecular Weight
332.26
Appearance
Beige Powder

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Purity
≥ 98%
Appearance
Beige Powder
ShelfLife
2 years
Storage
-20 °C
IUPACName
2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetic acid
Synonyms
E3 ligase Ligand 3; Thalidomide-Acid; Thalidomide-carboxylic acid; 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid; 2-[[2-(2,6-Dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetic acid
Boiling Point
660.5±55.0 °C (Predicted)
Density
1.606±0.06 g/cm3 (Predicted)
InChI Key
ZVWIXIGBWIEDFO-UHFFFAOYSA-N
InChI
InChI=1S/C15H12N2O7/c18-10-5-4-8(13(21)16-10)17-14(22)7-2-1-3-9(12(7)15(17)23)24-6-11(19)20/h1-3,8H,4-6H2,(H,19,20)(H,16,18,21)
Canonical SMILES
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)OCC(=O)O

Background Introduction

Thalidomide-O-COOH is a functionalized derivative of thalidomide, featuring a carboxylic acid group for straightforward conjugation. As a cereblon (CRBN) E3 ligase ligand, this molecule is widely used in the design and synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation applications in biomedical research and drug discovery.

Mechanism

Thalidomide-O-COOH binds selectively to the CRBN protein, a substrate receptor component of the CRL4 E3 ubiquitin ligase complex. When used as part of a PROTAC molecule, it acts as an E3 ligase recruiter. The carboxylic acid moiety allows for easy linker attachment, facilitating the covalent connection to a target protein ligand. Upon successful linking, the resulting bifunctional PROTAC molecule brings the E3 ligase and the target protein into close proximity, enabling ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

Thalidomide-O-COOH is a key building block in the synthesis of CRBN-based PROTACs, allowing researchers to design molecules for selective protein degradation of disease-relevant targets. It is ideal for chemical biology studies, mechanism-of-action investigations, and early-stage drug development in oncology, neurodegenerative diseases, and immune disorders. Additionally, it is utilized in developing next-generation targeted therapies with improved selectivity and reduced off-target effects.

• Carboxylic acid functionality enables versatile coupling with amine-containing partners for PROTAC assembly.
• Specifically designed for efficient and reliable CRBN E3 ligase recruitment in targeted protein degradation applications.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
Germany
Inquiry Basket